Long-Term Testosterone Therapy Carries Specific Risks That Require Monitoring, But Most Are Manageable
Long-term testosterone therapy is generally safe when properly monitored, with the most significant risks being erythrocytosis (elevated red blood cells) and potential prostate concerns, while recent high-quality evidence shows no increased cardiovascular or prostate cancer risk in appropriately selected patients 1, 2.
Key Risks by Clinical Significance
High-Priority Risks Requiring Active Monitoring
Erythrocytosis (Polycythemia)
- Most common clinically significant risk, occurring in 3-18% with transdermal formulations and up to 44% with intramuscular injections 3
- Requires regular hemoglobin/hematocrit monitoring throughout treatment 4
- Can increase thrombotic risk if unrecognized
- Management: Dose reduction or temporary discontinuation if hematocrit exceeds safe thresholds
Prostate Monitoring Requirements
- Prostate cancer risk remains controversial with "unknown level of risk" requiring long-term monitoring 3
- FDA labeling warns of increased risk of prostatic hypertrophy and carcinoma in geriatric patients, though conclusive evidence is lacking 4
- Recent meta-analysis of 41 RCTs found no statistically significant increase in prostate cancer events (OR 0.88; 95% CI: 0.52-1.51) 2
- Contraindicated in men with existing prostate cancer 4
Cardiovascular Safety: Recent Evidence vs. Historical Concerns
The cardiovascular risk profile has evolved significantly with new data:
Reassuring Recent Evidence:
- The TRAVERSE trial (2024)—the largest and highest-quality study—found no increase in major adverse cardiac events in 5,246 men followed for mean 27.1 months 1
- 2026 meta-analysis of 41 RCTs showed no significant MACE increase (OR 0.83; 95% CI: 0.52-1.32) 2
- Historical guideline data suggested neutral or possibly beneficial cardiovascular effects 3
Concerning Contradictory Evidence:
- 2025 real-world cohort study found 55% increased MACE risk with long-term use (HR 1.55; 95% CI: 1.19-2.01) 5
- 2019 UK study showed increased risk in first 6 months to 2 years of use (HR 1.35; 95% CI: 1.01-1.79), particularly in men aged 45-59 6
- One 2004 veterans study found increased composite endpoint of mortality/MI/stroke (HR 1.29) 7
Clinical Interpretation: The highest-quality randomized evidence (TRAVERSE) should guide practice, showing safety in appropriately selected patients. However, highest risk appears in the first 2 years of therapy and in younger men (45-59 years), requiring closer monitoring during this period 6.
Moderate-Risk Side Effects
Testicular Atrophy and Infertility
- Common, especially in young men 3
- Usually reversible with cessation 3
- Critical counseling point for men of reproductive age
Sleep Apnea
Dermatologic Effects
- Acne most frequent (0.6-9.1% depending on formulation) 8
- Skin reactions highly variable by delivery method: patches up to 66%, gels 5%, injections rare 3, 8
- Can significantly impact adherence despite being "non-severe" 8
Low-Risk or Rarely Clinically Significant
- Fluid retention: rarely clinically significant 3
- Benign prostatic hyperplasia: rarely clinically significant 3
- Gynecomastia: rare, usually reversible 3
- Lipid alterations: most studies show no change with physiologic doses 3
Critical Monitoring Algorithm
Baseline Requirements:
- Two fasting testosterone levels <10.4 nmol/L (300 ng/dL) with symptoms 1, 9
- Screen for cardiovascular disease, prostate cancer, elevated PSA 1
- Baseline hemoglobin/hematocrit 4
Ongoing Monitoring:
- Hemoglobin/hematocrit: periodically throughout treatment 4
- Symptom response assessment 9
- Prostate monitoring: long-term surveillance required 3
- Intensify cardiovascular monitoring in first 2 years, especially in men under 60 6
Common Pitfalls to Avoid
- Using testosterone in men without documented hypogonadism (symptoms + low testosterone on two occasions)
- Failing to monitor hematocrit, leading to unrecognized erythrocytosis
- Prescribing to men with active prostate cancer or recent cardiovascular events—these are contraindications
- Inadequate counseling of young men about fertility effects
- Assuming all formulations have equal risk profiles—injectable testosterone has highest erythrocytosis risk (up to 44%) 3
Formulation-Specific Considerations
Injectable testosterone carries highest erythrocytosis risk but lowest dermatologic reactions. Transdermal patches have highest skin reaction rates (up to 66%) but lower systemic risks. Oral formulations have lowest acne rates but carry hepatotoxicity concerns 3, 8.